Skip to main content
Explore URMC

menu

Gastric & Gastroesophageal Cancer: A Study of FPA144 Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer (FIGHT)

Research Question:
How safe and what is the tolerability of the new investigational compound, called FPA144, in combination with chemotherapy (a combination of 5-fluorouracil, oxaliplatin, and leucovorin called mFOLFOX6), for the treatment of gastric and/or gastroesophageal cancer and other solid tumors?

Basic Study Information

Purpose:
This study consists of 2 phases. The first phase (Phase 1) of the study will be open to patients who have gastrointestinal cancer and plan to receive a type of chemotherapy treatment called mFOLFOX6. The second phase (Phase 3) will include patients who have gastric or gastroesophageal cancer, whose physician plans to administer chemotherapy (mFOLFOX6) as therapy, and have a tumor that is FGFR2b positive.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03343301?term=FPA-144&rank=1
Study Reference #: IGIE17107

Lead Researcher (Principal Investigator)

Lead Researcher: Mohamedtaki Tejani, MD

Study Contact Information

Study Coordinator: Chris Le Feber
Phone: (585) 275-0407
Email: Chris_LeFeber@URMC.Rochester.edu

Additional Study Details

Return to Search